Image For Activity Cover
AACE Guideline Update: Developing a Diabetes Mellitus Comprehensive Care Plan
Release: 10/7/2022 | Expiration: 10/7/2023
Speaker Info
Role: Speaker
Lawrence Blonde, MD, FACP, MACE 
Ochsner Medical Center

Lawrence Blonde, MD, FACP, MACE, is Director of the Ochsner Diabetes Clinical Research Unit, in the Frank Riddick Diabetes Institute, Department of Endocrinology, at the Ochsner Medical Center, New Orleans, LA. Dr. Blonde is presently an Associate Editor for the journal Diabetes Care. He has been Chair of the Steering Committee of the National Diabetes Education Program (NDEP), a member of the AACE Board of Directors and the Board of Trustees of ACE and a former member of the ADA Board of Directors and former chair of the ADA Professional Practice Committee. Dr. Blonde was a co-author of the 2015 "American Association of Clinical Endocrinologists (AACE) and American College of Endocrinology (ACE) - Clinical Practice Guidelines For Developing A Diabetes Mellitus Comprehensive Care Plan." He was also a co-author of the 2020 AACE/ACE Comprehensive Type 2 Diabetes Management Algorithm.

Role: Moderator
S. Sethu K. Reddy, MD, MBA, FRCPC, FACP, MACE
Senior Associate Dean - Research
CMU College of Medicine

Dr. Sethu Reddy is the current President of the American Association of Clinical Endocrinology. He is the Senior Associate Dean - Research, Central Michigan University College of Medicine. He has previously been Chief of Adult Diabetes at Joslin Diabetes Center, Harvard, in Boston and Chairman of Endocrinology, Diabetes & Metabolism at Cleveland Clinic and a VP for US Medical Affairs at Merck. He completed his undergraduate education at Memorial University of Newfoundland and postgraduate training in Endocrinology & Metabolism at the University of Toronto and in Molecular & Cellular Physiology at Joslin Diabetes Center, Harvard Medical School, Boston in 1988. He completed his MBA in 2001. He is an internationally recognized speaker. In 2007, he received the distinction of Mastership in the American College of Endocrinology.
Accreditation Information

Accreditation Statements


Physicians and Physician Assistants

The American College of Endocrinology (ACE) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. The American College of Endocrinology (ACE) designates this enduring material for a maximum of 1.25 AMA PRA Category 1 Credit(s)TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.


Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.25 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. Only those who receive a passing score will be eligible for MOC credit.

Please allow two weeks for MOC points to appear within your account on the ABIM website. Participation information will be shared with the American Board of Internal Medicine (ABIM) through the Accreditation Council for Continuing Medical Education (ACCME) Program and Activity Reporting System (PARS).

Learning Objectives

Upon completion of the activity, participants should be able to: 

  • Apply the most up to date recommendations for management of comorbidities, including obesity, hypertension, dyslipidemia, retinopathy, neuropathy, diabetic/chronic kidney disease, and cardiovascular disease.
  • Describe new strategies for lifestyle therapy that includes healthy eating and behaviors, and physical activity is a foundational aspect of treatment for persons with diabetes, who also may have or are at risk for other cardiometabolic disease outcomes.
  • Analyze strategies for person-centered, team-based clinical decision making and improve the comprehensive care of persons with prediabetes and diabetes.

Target Audience

Endocrinologists, cardiologists, nephrologists, gastroenterologists/liver disease specialists, physician assistants, nurse practitioners, nurses, and primary care physicians.

Disclosure Policy

In accordance with the ACCME Standards for Commercial Support, The American Association of Clinical Endocrinology (AACE) requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any commercial interest. AACE resolves all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all their educational programs. Furthermore, AACE seeks to verify that all scientific research referred to, reported, or used in a CME/CE activity conforms to the generally accepted standards of experimental design, data collection, and analysis. AACE is committed to providing learners with high-quality CME.


The planners, reviewers, editors, staff, CME committee, and other members at the American Association of Clinical Endocrinology who control content have no relevant financial relationships to disclose.

Faculty Disclosures

Name  Relevant Financial Relationship   Ineligible Company  
Lawrence Blonde, MD, FACP, MACE Consulting Fees


  Consulting Fees Gilead Sciences, Inc
  Consulting Fees Corcept
  Consulting Fees Merck & Co
  Consulting Fees Salix
  Consulting Fees, Research Grant Novo Nordisk
  Consulting Fees, Honorarium, Research Grant Sanofi


All of the relevant financial relationships listed for these individuals have been mitigated.

All other faculty for this educational activity have no relevant financial relationships to disclose with ineligible companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

Disclosure of Unlabeled Use

AACE requires CME faculty (speakers) to disclose when products or procedures being discussed are off label, unlabeled, experimental and/or investigational, and any limitations on the information that is presented, such as data that are preliminary, or that represent ongoing research, interim analyses, and/or unsupported opinion. Faculty in this activity may discuss information about pharmaceutical agents that is outside of US Food and Drug Administration approved labeling. This information is intended solely for continuing medical education and is not intended to promote off-label use of these medications. AACE does not recommend the use of any agent outside of the labeled indications. If you have questions, contact the Medical Affairs Department of the manufacturer for the most recent prescribing information.


Availability: On-Demand
Expires on Oct 07, 2023
Cost: Member: $30.00
Non-Member: $50.00
Credit Offered:
1.25 CME Credits
1.25 ABIM-MOC Points
Powered By